Price movement over the last 24 hours
AdaptHealth Corp vs Nomura Holdings Inc — how do they compare? AdaptHealth Corp trades at $10.01 (market cap $1.38B), while Nomura Holdings Inc trades at $9.43 (market cap $27.73B). The key difference: Nomura Holdings Inc is far larger — about 20.1× AdaptHealth Corp's market cap, and Nomura Holdings Inc pays a 3.44% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | NMR | |
|---|---|---|
Market Cap | $1.38B | $27.73B |
Sector | Health | Financials |
52-Week High | $13.38 | $9.54 |
52-Week Low | $8.68 | $6.30 |
Enterprise Value | $3.33B | — |
Dividend Yield | — | 3.44% |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
Nomura Holdings (NMR) trades at $9.42, up 3.97% with a bullish technical signal. The stock shows strong fundamentals with record annual profit of $340.74B (20.49% margin) and revenue growth to $1.66T. Recent news highlights CEO pay increase following record performance and US expansion plans. Technical indicators show bullish momentum with RSI at neutral levels, while analyst consensus leans hold-heavy with 66.7% neutral rating.
Outlook remains positive with expanding profitability and strategic acquisitions, though recent earnings misses and rising debt-to-asset ratio (26.25%) present execution risks. The stock trades at attractive valuations (P/E 12.66, P/B 1.19) but faces integration challenges from Macquarie acquisition and geopolitical uncertainties affecting growth sustainability.
Trailing returns across standard periods
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →